| EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic S Gullapalli, A Roychowdhury, T Khaladkar, S Sawargave, R Janrao, ... Cancer Res. 78 (Suppl), 1701, 2018 | 17 | 2018 |
| Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice J Mookkan, S De, P Shetty, NM Kulkarni, V Devisingh, MS Jaji, ... Indian journal of pharmacology 46 (1), 46, 2014 | 12 | 2014 |
| Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer MK Gurjar, A Roychowdhury, TP Khaladkar, SP Sawargave, RA Janrao, ... US Patent App. 16/071,712, 2019 | 1 | 2019 |
| Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases S Narayanan, J Mookkan, J Kulathingal, N Surendran, G Singh, ... US Patent App. 13/809,604, 2014 | | 2014 |
| Dipeptidyl peptidase IV inhibitors G Balasubramanian, S Sakamuri, G Singh, S Dharmalingam, FP Xavier, ... US Patent 8,466,145, 2013 | | 2013 |
| ANTI-INFLAMMATORY AND ANALGESIC EFFECT OF HDAC INHIBITORS; SAHA AND MS-275 IN INFLAMMATORY PAIN MODELS H Rahuman, J Gunasekaran, MM Muley, Z Attari, NM Lemos, PK Singh, ... INFLAMMATION RESEARCH 61, S22-S23, 2012 | | 2012 |
| OCID15314: A NOVEL HDAC INHIBITOR WITH POTENT ANTI-MULTIPLE MYELOMA EFFECTS J Kulathingal, J Mookkan, ND Reddy, D Jayaraman, S Johny, N Saranya, ... ANNALS OF ONCOLOGY 23, 27-27, 2012 | | 2012 |
| Combination of Vildagliptin and Rosiglitazone Ameliorates Non-lcoholic Fatty Liver Disease in C57BL/6 Mice J Mookkan, S De, P Shetty, NM Kulkarni, V Devisingh, MS Jaji, ... DIABETES 60, A284-A284, 2011 | | 2011 |
| Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and 2 anti-rheumatic effects A Saxena, J Kulathingal, G Vijaykanth, J Raghul, N Rajesh, ... | | |
